Kohesio: discover EU projects in your region

project info
Start date: 1 July 2020
End date: n/a
Project website: link
funding
Fund: European Regional Development Fund (ERDF)
Total budget: 659 999,75 €
EU contribution: 494 999,78 € (75%)
programme
Programming period: 2014-2021
Managing authority: Sergio Negro

THERAPEUTIC EFFICACY OF HYPERIMMUNE IMMUNOGLOBULINS ISOLATED FROM PLASMA OF CONVALESCENT COVID-19 PATIENTS

OBJECTIVE OF THE PROJECT IS THE RAPID ISOLATION AND PRODUCTION OF HYPERIMMUNE IMMUNOGLOBULINS FROM PLASMA OF PATIENTS CURED BY COVID-19 INFECTION, IN ORDER TO PROVIDE A NEW THERAPEUTIC TOOL FOR THE MOST CRITICAL PATIENTS AND A POSSIBLE PREVENTIVE CARE FOR THOSE EXPOSED AND AT RISK OF INFECTION (E.G. MEDICAL AND PARAMEDICAL STAFF). HYPERIMMUNE IMMUNOGLOBULIN THERAPY WOULD OVERCOME THE SAFETY PROBLEMS CREATED BY THE USE OF PLASMA AND IS BASED ON THE PRINCIPLE OF PROVIDING THE PATIENT WITH ‘PASSIVE (OR ADOPTIVE) IMMUNISATION’ DUE TO ANTIBODIES ALREADY FORMED BY ANOTHER SUBJECT WHO HAS ALREADY RECOVERED FROM THE INFECTION. GIVEN THE ‘PASSIVE’ NATURE OF IMMUNISATION, WHICH DOES NOT REQUIRE A RESPONSE BY THE PATIENT’S IMMUNE SYSTEM, TREATMENT COULD ALSO BE USED EFFECTIVELY IN THE CASES OF DEFUNCT, ELDERLY AND IMMUNODEPRESSI.IN THIS OPTICS, THE PRODUCTION OF HYPERIMMUNE IMMUNOGLOBULINS COULD BE A ‘PRE-VACCINE’,

Flag of Italy  Province of Avellino, Italy